2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension

Journal of the Chinese Medical Association

Volumn 78, Issue 1, 2015, Pages 1-47

  Chiang, Chern En ^a   Wang, Tzung Dau ^b   Ueng, Kwo Chang ^c   Lin, Tsung Hsien ^d   Yeh, Hung I ^e   Chen, Chung Yin ^f   Wu, Yih Jer ^e   Tsai, Wei Chuan ^g   Chao, Ting Hsing ^g   Chen, Chen Huan ^a,h   Chu, Pao Hsien ⁱ   Chao, Chia Lun ^j   Liu, Ping Yen ^g   Sung, Shih Hsien ^a   Cheng, Hao Min ^a,h   Wang, Kang Ling ^a   Li, Yi Heng ^g   Chiang, Fu Tien ^b,j   Chen, Jyh Hong ^g   Chen, Wen Jone ^j,k   Yeh, San Jou ⁱ   Lin, Shing Jong ^a,h   more..

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f KUANG TIEN GENERAL HOSPITAL   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^k Division of Nephrology Poh Ai Hospital   (Taiwan)

more..

Author keywords

Asia; Guidelines; Hypertension; Taiwan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ORAL CONTRACEPTIVE AGENT; RENIN INHIBITOR;

AGING; ARTICLE; ASIA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; LABORATORY TEST; LIFESTYLE MODIFICATION; MASKED HYPERTENSION; MATERNAL HYPERTENSION; MEDICAL HISTORY; MEDICAL SOCIETY; MONOTHERAPY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; RESISTANT HYPERTENSION; SCREENING TEST; SMOKING CESSATION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TAIWAN; WEIGHT REDUCTION; WHITE COAT HYPERTENSION; FEMALE; HEART DISEASE;

FEMALE; HEART DISEASES; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TAIWAN;

EID: 84922673523     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2014.11.005     Document Type: Article

References (454)

1. Ezzati M., Riboli E. Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 2013, 369:954-964.
2. Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
3. Murray C.J.L., Lopez A.D. Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
4. Lawes C.M., Vander H.S., Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008, 371:1513-1518.
5. Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B., D'Agostino R.B., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the framingham heart study. JAMA 2002, 287:1003-1010.
6. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
7. Ikeda N., Sapienza D., Guerrero R., Aekplakorn W., Naghavi M., Mokdad A.H., et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ 2014, 92:10C-19C.
8. Su T.C., Bai C.H., Chang H.Y., You S.L., Chien K.L., Chen M.F., et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens 2008, 26:600-606.
9. Chiang C.E., Wang T.D., Li Y.H., Lin T.H., Chien K.L., Yeh H.I., et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010, 109:740-773.
10. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013, 31:1281-1357.
11. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311:507-520.
12. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:e57-185.
13. Medicine Io Clinical practice guidelines we can trust 2011, National Academies Press, Washington DC. http://www.iom.edu/Reports/2011.
14. Choi K.M., Park H.S., Han J.H., Lee J.S., Lee J., Ryu O.H., et al. Prevalence ofprehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006, 24:1515-1521.
15. Ueshima H., Sekikawa A., Miura K., Turin T.C., Takashima N., Kita Y., et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008, 118:2702-2709.
16. Kim A.S., Johnston S.C. Global variation in the relative burden of stroke and ischemic heart disease. Circulation 2011, 124:314-323.
17. O'Donnell M.J., Xavier D., Liu L., Zhang H., Chin S.L., Rao-Melacini P., et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010, 376:112-123.
18. Perkovic V., Huxley R., Wu Y., Prabhakaran D., MacMahon S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50:991-997.
19. Martiniuk A.L., Lee C.M., Lawes C.M., Ueshima H., Suh I., Lam T.H., et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. JHypertens 2007, 25:73-79.
20. Rodgers A., Chapman N., Woodward M., Liu L.S., Colman S., Lee A., et al. Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. JHypertens 2004, 22:653-659.
21. Chien K.L., Hsu H.C., Sung F.C., Su T.C., Chen M.F., Lee Y.T. Incidence of hypertension and risk of cardiovascular events among ethnic Chinese: report from a community-based cohort study in Taiwan. J Hypertens 2007, 25:1355-1361.
22. Ong K.L., Cheung B.M.Y., Man Y.B., Lau C.P., Lam K.S.L. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75.
23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157:2413-2446.
24. Pan W.H., Chang H.Y., Yeh W.T., Hsiao S.Y., Hung Y.T. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. J HumHypertens 2001, 15:793-798.
25. Liu P.Y., Chang C.L., Lin S.S., Chen J.H. Different effect of hypertension guideline-guided intervention on blood pressure goal-achieving rate on newly or poorly controlled hypertension subjects: a 6 months' experience in Taiwan. Acta Cardiol Sin 2014, (Suppl). [in press].
26. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
27. Pickering T.G., Hall J.E., Appel L.J., Falkner B.E., Graves J., Hill M.N., et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005, 111:697-716.
28. Fagard R.H., De Cort P. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly. Hypertension 2010, 56:56-61.
29. Fedorowski A., Stavenow L., Hedblad B., Berglund G., Nilsson P.M., Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 2010, 31:85-91.
30. Franklin S.S., Larson M.G., Khan S.A., Wong N.D., Leip E.P., Kannel W.B., et al. Does the relation of blood pressure to coronary heart disease risk change with aging?: the Framingham Heart Study. Circulation 2001, 103:1245-1249.
31. Alli C., Avanzini F., Bettelli G., Colombo F., Torri V., Tognoni G., et al. The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med 1999, 159:1205-1212.
32. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014, 383:1899-1911.
33. Okayama A., Kadowaki T., Okamura T., Hayakawa T., Ueshima H. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80*). J Hypertens 2006, 24:459-462. on behalf of The ND.
34. Williams B., Lindholm L.H., Sever P. Systolic pressure is all that matters. Lancet 2008, 371:2219-2221.
35. Wang J.G., Staessen J.A., Franklin S.S., Fagard R., Gueyffier F. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005, 45:907-913.
36. Parati G., Stergiou G., O'Brien E., Asmar R., Beilin L., Bilo G., et al. European Society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014, 32:1359-1366.
37. Clement D.L., De Buyzere M.L., De Bacquer D.A., de Leeuw P.W., Duprez D.A., Fagard R.H., et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003, 348:2407-2415.
38. Conen D., Bamberg F. Noninvasive 24-h ambulatory blood pressure andcardiovascular disease: a systematic review and meta-analysis. JHypertens 2008, 26:1290-1299.
39. Pickering T.G., Shimbo D., Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006, 354:2368-2374.
40. Sega R., Facchetti R., Bombelli M., Cesana G., Corrao G., Grassi G., et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005, 111:1777-1783.
41. Fagard R.H., Celis H., Thijs L., Staessen J.A., Clement D.L., De Buyzere M.L., et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008, 51:55-61.
42. Hansen T.W., Li Y., Boggia J., Thijs L., Richart T., Staessen J.A. Predictive role of the nighttime blood pressure. Hypertension 2011, 57:3-10.
43. Hermida R.C., Ayala D.E., Mojon A., Fernandez J.R. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011, 58:1165-1173.
44. Turner J.R., Viera A.J., Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med August 5 2014, [Epub ahead of print].
45. Kario K., Ishikawa J., Pickering T.G., Hoshide S., Eguchi K., Morinari M., et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res 2006, 29:581-587.
46. Stergiou G.S., Nasothimiou E.G., Roussias L.G. Morning hypertension assessed by home or ambulatory monitoring: different aspects of the same phenomenon?. J Hypertens 2010, 28:1846-1853.
47. Hoshide S., Kario K. Early morning hypertension: a narrative review. Blood Press Monit 2013, 18:291-296.
48. Kario K., Pickering T.G., Umeda Y., Hoshide S., Hoshide Y., Morinari M., et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003, 107:1401-1406.
49. Metoki H., Ohkubo T., Kikuya M., Asayama K., Obara T., Hashimoto J., et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension 2006, 47:149-154.
50. Li Y., Thijs L., Hansen T.W., Kikuya M., Boggia J., Richart T., et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 2010, 55:1040-1048.
51. Niiranen T.J., Hanninen M.R., Johansson J., Reunanen A., Jula A.M. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 2010, 55:1346-1351.
52. Ward A.M., Takahashi O., Stevens R., Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens 2012, 30:449-456.
53. Stergiou G.S., Argyraki K.K., Moyssakis I., Mastorantonakis S.E., Achimastos A.D., Karamanos V.G., et al. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens 2007, 20:616-621.
54. Gaborieau V., Delarche N., Gosse P. Ambulatory blood pressure monitoring versus self-measurement of blood pressure at home: correlation with target organ damage. J Hypertens 2008, 26:1919-1927.
55. Bliziotis I.A., Destounis A., Stergiou G.S. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens 2012, 30:1289-1299.
56. Pickering T.G., White W.B. ASH Position Paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2008, 10:850-855.
57. Parati G., Stergiou G.S., Asmar R., Bilo G., de Leeuw P., Imai Y., et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010, 24:779-785.
58. McManus R.J., Mant J., Haque M., Bray E.P., Bryan S., Greenfield S.M., et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the tasmin-sr randomized clinical trial. JAMA 2014, 312:799-808.
59. Hansen T.W., Kikuya M., Thijs L., Bjorklund-Bodegard K., Kuznetsova T., Ohkubo T., et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individuals. J Hypertens 2007, 25:1554-1564.
60. Stergiou G.S., Asayama K., Thijs L., Kollias A., Niiranen T.J., Hozawa A., et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension 2014, 63:675-682.
61. Franklin S.S., Thijs L., Hansen T.W., Li Y., Boggia J., Kikuya M., et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012, 59:564-571.
62. Sung S.H., Cheng H.M., Wang K.L., Yu W.C., Chuang S.Y., Ting C.T., et al. White coat hypertension is more risky than prehypertension: important role of arterial wave reflections. Hypertension 2013, 61:1346-1353.
63. Mancia G., Bombelli M., Brambilla G., Facchetti R., Sega R., Toso E., et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013, 62:168-174.
64. Sega R., Trocino G., Lanzarotti A., Carugo S., Cesana G., Schiavina R., et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001, 104:1385-1392.
65. Puato M., Palatini P., Zanardo M., Dorigatti F., Tirrito C., Rattazzi M., et al. Increase in carotid intima-media thickness in grade I hypertensive subjects: white-coat versus sustained hypertension. Hypertension 2008, 51:1300-1305.
66. Kario K., Pickering T.G. White-coat hypertension or white-coat hypertension syndrome: which is accompanied by target organ damage?. Arch Intern Med 2000, 160:3497-3498.
67. Mancia G., Bombelli M., Facchetti R., Madotto F., Quarti-Trevano F., Grassi G., et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009, 27:1672-1678.
68. De Nicola L., Gabbai F.B., Agarwal R., Chiodini P., Borrelli S., Bellizzi V., et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol 2013, 61:2461-2467.
69. Pierdomenico S.D., Lapenna D., Bucci A., Di Tommaso R., Di Mascio R., Manente B.M., et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005, 18:1422-1428.
70. Muxfeldt E.S., Fiszman R., de Souza F., Viegas B., Oliveira F.C., Salles G.F. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 2012, 59:384-389.
71. Shimbo D., Newman J.D., Schwartz J.E. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens 2012, 25:664-671.
72. Hanninen M.R., Niiranen T.J., Puukka P.J., Mattila A.K., Jula A.M. Determinants of masked hypertension in the general population: the Finn-Home study. J Hypertens 2011, 29:1880-1888.
73. Franklin S.S., Thijs L., Li Y., Hansen T.W., Boggia J., Liu Y., et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013, 61:964-971.
74. Gorostidi M., Sarafidis P.A., de la Sierra A., Segura J., de la Cruz J.J., Banegas J.R., et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis 2013, 62:285-294.
75. Drager L.F., Diegues-Silva L., Diniz P.M., Bortolotto L.A., Pedrosa R.P., Couto R.B., et al. Obstructive sleep apnea, masked hypertension, and arterial stiffness in men. Am J Hypertens 2010, 23:249-254.
76. Fagard R.H., Cornelissen V.A. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens 2007, 25:2193-2198.
77. Pierdomenico S.D., Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011, 24:52-58.
78. Peacock J., Diaz K.M., Viera A.J., Schwartz J.E., Shimbo D. Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens 2014, 28:521-528.
79. Wen C.P., Cheng T.Y., Tsai M.K., Chang Y.C., Chan H.T., Tsai S.P., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008, 371:2173-2182.
80. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008, 359:2195-2207.
81. Karamanoglu M., O'Rourke M.F., Avolio A.P., Kelly R.P. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. Eur Heart J 1993, 14:160-167.
82. Wang K.L., Cheng H.M., Chuang S.Y., Spurgeon H.A., Ting C.T., Lakatta E.G., et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?. J Hypertens 2009, 27:461-467.
83. Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
84. Hashimoto J., Imai Y., O'Rourke M.F. Monitoring of antihypertensive therapy for reduction in left ventricular mass. Am J Hypertens 2007, 20:1229-1233.
85. Agabiti-Rosei E., Mancia G., O'Rourke M.F., Roman M.J., Safar M.E., Smulyan H., et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007, 50:154-160.
86. Huang C.M., Wang K.L., Cheng H.M., Chuang S.Y., Sung S.H., Yu W.C., et al. Central versus ambulatory blood pressure in the prediction of all-cause and cardiovascular mortalities. J Hypertens 2011, 29:454-459.
87. Benetos A., Tsoucaris-Kupfer D., Favereau X., Corcos T., Safar M. Carotid artery tonometry: an accurate non-invasive method for central aortic pulse pressure evaluation. J Hypertens Suppl 1991, 9:S144-S145.
88. Cheng H.M., Wang K.L., Chen Y.H., Lin S.J., Chen L.C., Sung S.H., et al. Estimation of central systolic blood pressure using an oscillometric blood pressure monitor. Hypertens Res 2010, 33:592-599.
89. Kikuya M., Hansen T.W., Thijs L., Bjorklund-Bodegard K., Kuznetsova T., Ohkubo T., et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007, 115:2145-2152.
90. Chen C.H., Ting C.T., Lin S.J., Hsu T.L., Ho S.J., Chou P., et al. Which arterial and cardiac parameters best predict left ventricular mass?. Circulation 1998, 98:422-428.
91. Chuang S.Y., Bai C.H., Chen W.H., Lien L.M., Pan W.H. Fibrinogen independently predicts the development of ischemic stroke in a Taiwanese population: CVDFACTS study. Stroke 2009, 40:1578-1584.
92. Cheng H.M., Chuang S.Y., Sung S.H., Yu W.C., Pearson A., Lakatta E.G., et al. Derivation and validation of diagnostic thresholds for central blood pressure measurements based on long-term cardiovascular risks. J Am Coll Cardiol 2013, 62:1780-1787.
93. Cheng H.M., Sung S.H., Chuang S.Y., Pearson A., Tufanaru C., White S., et al. Diagnostic performance of a stand-alone central blood pressure monitor: application of central blood pressure in the diagnosis of high blood pressure. Am J Hypertens 2014, 27:382-391.
94. Parati G., Ochoa J.E., Lombardi C., Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013, 10:143-155.
95. Floras J.S. Blood pressure variability: a novel and important risk factor. Can J Cardiol 2013, 29:557-563.
96. Sander D., Kukla C., Klingelhofer J., Winbeck K., Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000, 102:1536-1541.
97. Mancia G., Bombelli M., Facchetti R., Madotto F., Corrao G., Trevano F.Q., et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007, 49:1265-1270.
98. Hansen T.W., Thijs L., Li Y., Boggia J., Kikuya M., Bjorklund-Bodegard K., et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension 2010, 55:1049-1057.
99. Mancia G., Di Rienzo M., Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 1993, 21:510-524.
100. Chen C.H., Ting C.T., Lin S.J., Hsu T.L., Chou P., Kuo H.S., et al. Relation between diurnal variation of blood pressure and left ventricular mass in a Chinese population. Am J Cardiol 1995, 75:1239-1243.
101. Kikuya M., Ohkubo T., Metoki H., Asayama K., Hara A., Obara T., et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 2008, 52:1045-1050.
102. Kawai T., Ohishi M., Kamide K., Onishi M., Takeya Y., Tatara Y., et al. The impact of visit-to-visit variability in blood pressure on renal function. Hypertens Res 2012, 35:239-243.
103. Brickman A.M., Reitz C., Luchsinger J.A., Manly J.J., Schupf N., Muraskin J., et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 2010, 67:564-569.
104. Rothwell P.M., Howard S.C., Dolan E., O'Brien E., Dobson J.E., Dahlof B., et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010, 9:469-480.
105. Eguchi K., Hoshide S., Schwartz J.E., Shimada K., Kario K. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. Am J Hypertens 2012, 25:962-968.
106. Muntner P., Shimbo D., Tonelli M., Reynolds K., Arnett D.K., Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 2011, 57:160-166.
107. Hall W.D. Resistant hypertension, secondary hypertension, and hypertensive crises. Cardiol Clin 2002, 20:281-289.
108. Safian R.D., Textor S.C. Renal-Artery Stenosis. N Engl J Med 2001, 344:431-442.
109. Douma S., Petidis K., Doumas M., Papaefthimiou P., Triantafyllou A., Kartali N., et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921-1926.
110. Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A., Rutherford J.C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
111. Wu V.C., Chueh S.C., Chang H.W., Lin W.C., Liu K.L., Li H.Y., et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM 2008, 101:13-22.
112. Lawes C.M., Rodgers A., Bennett D.A., Parag V., Suh I., Ueshima H., et al. Blood pressure and cardiovascular disease in the Asia Pacific region. JHypertens 2003, 21:707-716.
113. Rodriguez C.J., Swett K., Agarwal S.K., Folsom A.R., Fox E.R., Loehr L.R., et al. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. JAMA Intern Med 2014, 174:1252-1261.
114. Wright J.T., Fine L.J., Lackland D.T., Ogedegbe G., Dennison Himmelfarb C.R. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014, 160:499-503.
115. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
116. Navar-Boggan A.M., Pencina M.J., Williams K., Sniderman A.D., Peterson E.D. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA 2014, 311:1424-1429.
117. Ambrosius W.T., Sink K.M., Foy C.G., Berlowitz D.R., Cheung A.K., Cushman W.C., et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials June 5 2014, [Epub ahead of print].
118. Stewart I.M. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979, 1:861-865.
119. Rabkin S.W., Waheed A., Poulter R.S., Wood D. Myocardial perfusion pressure in patients with hypertension and coronary artery disease: implications for DBP targets in hypertension management. J Hypertens 2013, 31:975-982.
120. Cooper-DeHoff R.M., Gong Y., Handberg E.M., Bavry A.A., Denardo S.J., Bakris G.L., et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010, 304:61-68.
121. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334:13-18.
122. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
123. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265:3255-3264.
124. Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G., Birkenhager W.H., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
125. Liu L., Wang J.G., Gong L., Liu G., Staessen J.A. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. JHypertens 1998, 16:1823-1829. for the Systolic Hypertension in China Collaborative G.
126. Messerli F.H., Mancia G., Conti C.R., Hewkin A.C., Kupfer S., Champion A., et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006, 144:884-893.
127. Sleight P., Redon J., Verdecchia P., Mancia G., Gao P., Fagard R., et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009, 27:1360-1369.
128. Bangalore S., Messerli F.H., Wun C.C., Zuckerman A.L., DeMicco D., Kostis J.B., et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010, 31:2897-2908.
129. Redon J., Mancia G., Sleight P., Schumacher H., Gao P., Pogue J., et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012, 59:74-83.
130. Verdecchia P., Angeli F., Mazzotta G., Garofoli M., Reboldi G. Aggressive blood pressure lowering is dangerous: the J-curve: con side of the arguement. Hypertension 2014, 63:37-40.
131. Boutitie F., Gueyffier F., Pocock S., Fagard R., Boissel J.P. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002, 136:438-448. for the IPSC.
132. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985, 291:97-104.
133. Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005, 23:2157-2172.
134. Verdecchia P., Staessen J.A., Angeli F., de Simone G., Achilli A., Ganau A., et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009, 374:525-533.
135. Zhang Y., Zhang X., Liu L., Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J 2011, 32:1500-1508.
136. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
137. Howard B.V., Roman M.J., Devereux R.B., Fleg J.L., Galloway J.M., Henderson J.A., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008, 299:1678-1689.
138. Group UKPDS Tight blood pressure control and risk of macrovascular and microvascular complications in type 2diabetes: UKPDS 38. BMJ 1998, 317:703-713.
139. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
140. Okin P.M., Hille D.A., Kjeldsen S.E., Dahlof B., Devereux R.B. Impact of lower achieved blood pressure on outcomes in hypertensive patients. JHypertens 2012, 30:802-810.
141. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., Marks R.G., Kowey P., Messerli F.H., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
142. Reboldi G., Gentile G., Angeli F., Ambrosio G., Mancia G., Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. J Hypertens 2011, 29:1253-1269.
143. Bangalore S., Kumar S., Lobach I., Messerli F.H. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011, 123:2799-2810.
144. McBrien K., Rabi D.M., Campbell N., Barnieh L., Clement F., Hemmelgarn B.R., et al. Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2012, 172:1296-1303.
145. Arguedas J.A., Leiva V., Wright J.M. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 2013, 10:CD008277.
146. Tu S.T., Chang S.J., Chen J.F., Tien K.J., Hsiao J.Y., Chen H.C., et al. Prevention of diabetic nephropathy by tight target control in an Asian population with type 2 diabetes mellitus: a 4-year prospective analysis. Arch Intern Med 2010, 170:155-161.
147. Chan J.C., So W.Y., Yeung C.Y., Ko G.T., Lau I.T., Tsang M.W., et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care 2009, 32:977-982.
148. Yu N.C., Su H.Y., Chiou S.T., Yeh M.C., Yeh S.W., Tzeng M.S., et al. Trends of ABC control 2006-2011: a National Survey of Diabetes Health Promotion Institutes in Taiwan. Diabetes Res Clin Pract 2013, 99:112-119.
149. Li H.Y., Jiang Y.D., Chang C.H., Chung C.H., Lin B.J., Chuang L.M. Mortality trends in patients with diabetes in Taiwan: a nationwide survey in 2000-2009. J Formos Med Assoc 2012, 111:645-650.
150. Weber M.A., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G., et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014, 32:3-15.
151. Association AD Standards of medical care in diabetes-2014. Diabetes Care 2014, 37:S14-S80.
152. Shimamoto K., Ando K., Fujita T., Hasebe N., Higaki J., Horiuchi M., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014, 37:253-387.
153. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014, 104:1-52.
154. Dasgupta K., Quinn R.R., Zarnke K.B., Rabi D.M., Ravani P., Daskalopoulou S.S., et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014, 30:485-501.
155. Yusuf S., Hawken S., Ôunpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
156. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
157. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
158. Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. E Engl J Med 2004, 351:2058-2068.
159. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368: 581-588.
160. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004, 292:2217-2225.
161. Sipahi I., Tuzcu E.M., Schoenhagen P., Wolski K.E., Nicholls S.J., Balog C., et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006, 48:833-838.
162. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007, 356:1503-1516.
163. Bangalore S., Kumar S., Volodarskiy A., Messerli F.H. Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart 2013, 99:601-613.
164. Thompson A.M., Hu T., Eshelbrenner C.L., Reynolds K., He J., Bazzano L.A. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension. JAMA 2011, 305:913-922.
165. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
166. Czernichow S., Zanchetti A., Turnbull F., Barzi F., Ninomiya T., Kengne A.P., et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. JHypertens 2011, 29:4-16.
167. Bangalore S., Gong Y., Cooper-DeHoff R.M., Pepine C.J., Messerli F.H. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol 2014, 64:784-793.
168. Furie K.L., Kasner S.E., Adams R.J., Albers G.W., Bush R.L., Fagan S.C., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:227-276.
169. He J., Zhang Y., Xu T., Zhao Q., Wang D., Chen C.S., et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014, 311:479-489.
170. Benavente O.R., Coffey C.S., Conwit R., Hart R.G., McClure L.A., Pearce L.A., et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013, 382:507-515.
171. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1588.
172. Anderson C.S., Huang Y., Arima H., Heeley E., Skulina C., Parsons M.W., et al. Effects of Early Intensive Blood Pressure-Lowering Treatment on the Growth of Hematoma and Perihematomal Edema in Acute Intracerebral Hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010, 41:307-312.
173. Post-stroke antihypertensive treatment study A preliminary result. Chin Med J (Engl) 1995, 108:710-717.
174. Lancet Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack 2001, 358:1033-1041.
175. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A., et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. N Engl J Med 2008, 359:1225-1237.
176. Miettinen H., Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996, 27:2033-2039.
177. Jafar T.H., Stark P.C., Schmid C.H., Landa M., Maschio G., Marcantoni C., et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001, 60:1131-1140.
178. Nitsch D., Grams M., Sang Y., Black C., Cirillo M., Djurdjev O., et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013, 346:f324.
179. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
180. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
181. Klahr S., Levey A.S., Beck G.J., Caggiula A.W., Hunsicker L., Kusek J.W., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994, 330:877-884.
182. Wright J.T., Bakris G., Greene T., Agodoa L.Y., Appel L.J., Charleston J., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
183. Ruggenenti P., Perna A., Loriga G., Ganeva M., Ene-Iordache B., Turturro M., et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005, 365:939-946.
184. Arguedas J.A., Perez M.I., Wright J.M. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009, (3):CD004349.
185. Upadhyay A., Earley A., Haynes S.M., Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011, 154:541-548.
186. Kovesdy C.P., Lu J.L., Molnar M.Z., Ma J.Z., Canada R.B., Streja E., et al. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014, 174:1442-1449.
187. Peterson J.C., Adler S., Burkart J.M., Greene T., Hebert L.A., Hunsicker L.G., et al. Blood pressure control, proteinuria, and the progression of renal disease the modification of diet in renal disease study. Ann Intern Med 1995, 123:754-762.
188. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
189. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
190. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
191. Port F.K., Hulbert-Shearon T.E., Wolfe R.A., Bloembergen W.E., Golper T.A., Agodoa L.Y., et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999, 33:507-517.
192. Stidley C.A., Hunt W.C., Tentori F., Schmidt D., Rohrscheib M., Paine S., et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006, 17:513-520.
193. Myers O.B., Adams C., Rohrscheib M.R., Servilla K.S., Miskulin D., Bedrick E.J., et al. Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol 2010, 21:1970-1978.
194. Mailloux L.U., Haley W.E. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998, 32:705-719.
195. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45(4 Suppl 3):S1-153.
196. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008, 31:2115-2127.
197. Ogihara T., Saruta T., Rakugi H., Matsuoka H., Shimamoto K., Shimada K., et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010, 56:196-202.
198. Ogihara T., Kikuchi K., Matsuoka H., Fujita T., Higaki J., Horiuchi M., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009, 32:3-107.
199. Gueyffier F., Bulpitt C., Boissel J.P., Schron E., Ekbom T., Fagard R., et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999, 353:793-796.
200. Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D., et al. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008, 358:1887-1898.
201. Ariesen M.J., Claus S.P., Rinkel G.J., Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003, 34:2060-2065.
202. Wang K.L., Chiang C.E. Optimal international normalized ratio for atrial fibrillation in asians and Japanese. Circ J 2013, 77:2242-2243.
203. Chiang C.E., Wang K.L., Lip G.Y. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014, 111:789-797.
204. Toyoda K., Yasaka M., Uchiyama S., Nagao T., Gotoh J., Nagata K., et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010, 41:1440-1444.
205. Arima H., Anderson C., Omae T., Woodward M., MacMahon S., Mancia G., et al. Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke 2012, 43:1675-1677.
206. Hart R.G., Diener H.C., Yang S., Connolly S.J., Wallentin L., Reilly P.A., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517.
207. Hankey G.J., Stevens S.R., Piccini J.P., Lokhnygina Y., Mahaffey K.W., Halperin J.L., et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014, 45:1304-1312.
208. Hylek E.M., Held C., Alexander J.H., Lopes R.D., De Caterina R., Wojdyla D.M., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014, 63:2141-2147.
209. Kokubo Y. Prevention of hypertension and cardiovascular diseases: a comparison of lifestyle factors in Westerners and East Asians. Hypertension 2014, 63:655-660.
210. Elmer P.J., Obarzanek E., Vollmer W.M., Simons-Morton D., Stevens V.J., Young D.R., et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006, 144:485-495.
211. Troost J.P., Rafferty A.P., Luo Z., Reeves M.J. Temporal and regional trends in the prevalence of healthy lifestyle characteristics: United States, 1994-2007. Am J Public Health 2012, 102:1392-1398.
212. Mente A., O'Donnell M.J., Rangarajan S., McQueen M.J., Poirier P., Wielgosz A., et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med 2014, 371:601-611.
213. Pimenta E., Gaddam K.K., Oparil S., Aban I., Husain S., Dell'Italia L.J., et al. Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension: results From a Randomized Trial. Hypertension 2009, 54:475-481.
214. Chen J., Gu D., Huang J., Rao D.C., Jaquish C.E., Hixson J.E., et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet 2009, 373:829-835.
215. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hubbard V.S., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63(25 Pt B):2960-2984.
216. Mozaffarian D., Fahimi S., Singh G.M., Micha R., Khatibzadeh S., Engell R.E., et al. Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014, 371:624-634.
217. O'Donnell M., Mente A., Rangarajan S., McQueen M.J., Wang X., Liu L., et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014, 371:612-623.
218. O'Donnell M.J., Yusuf S., Mente A., Gao P., Mann J.F., Teo K., et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011, 306:2229-2238.
219. Graudal N., Jurgens G., Baslund B., Alderman M.H. Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis. Am J Hypertens 2014, 27:1129-1137.
220. Chien K.L., Hsu H.C., Chen P.C., Su T.C., Chang W.T., Chen M.F., et al. Urinary sodium and potassium excretion and risk of hypertension in Chinese: report from a community-based cohort study in Taiwan. JHypertens 2008, 26:1750-1756.
221. Cook N.R., Cutler J.A., Obarzanek E., Buring J.E., Rexrode K.M., Kumanyika S.K., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885.
222. Dickinson H.O., Mason J.M., Nicolson D.J., Campbell F., Beyer F.R., Cook J.V., et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006, 24:215-233.
223. Puddey I.B., Beilin L.J., Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987, 1:647-651.
224. Cushman W.C., Cutler J.A., Hanna E., Bingham S.F., Follmann D., Harford T., et al. Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med 1998, 158:1197-1207.
225. Xin X., He J., Frontini M.G., Ogden L.G., Motsamai O.I., Whelton P.K. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001, 38:1112-1117.
226. Neter J.E., Stam B.E., Kok F.J., Grobbee D.E., Geleijnse J.M. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003, 42:878-884.
227. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096.
228. Chen Z., Yang G., Offer A., Zhou M., Smith M., Peto R., et al. Body mass index and mortality in China: a 15-year prospective study of 220 000 men. Int J Epidemiol 2012, 41:472-481.
229. Wing R.R., Bolin P., Brancati F.L., Bray G.A., Clark J.M., Coday M., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013, 369:145-154.
230. Primatesta P., Falaschetti E., Gupta S., Marmot M.G., Poulter N.R. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001, 37:187-193.
231. Hsieh F.I., Chiou H.Y. Stroke: morbidity, risk factors, and care in taiwan. JStroke 2014, 16:59-64.
232. Appel L.J., Moore T.J., Obarzanek E., Vollmer W.M., Svetkey L.P., Sacks F.M., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336:1117-1124.
233. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3-10.
234. Blumenthal J.A., Babyak M.A., Hinderliter A., Watkins L.L., Craighead L., Lin P.H., et al. Effects of the DASH dietalone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med 2010, 170:126-135.
235. Struijk E.A., May A.M., Wezenbeek N.L., Fransen H.P., Soedamah-Muthu S.S., Geelen A., et al. Adherence to dietary guidelines and cardiovascular disease risk in the EPIC-NL cohort. Int J Cardiol 2014, 176:354-359.
236. Fung T.T., Chiuve S.E., McCullough M.L., Rexrode K.M., Logroscino G., Hu F.B. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008, 168:713-720.
237. Whelton S.P., Chin A., Xin X., He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
238. Cornelissen V.A., Fagard R.H. Effects of Endurance Training on Blood Pressure, Blood Pressure-Regulating Mechanisms, and Cardiovascular Risk Factors. Hypertension 2005, 46:667-675.
239. Turnbull F., Neal B., Algert C., Chalmers J., Chapman N., Cutler J., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
240. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
241. Yano Y., Briasoulis A., Bakris G.L., Hoshide S., Wang J.G., Shimada K., et al. Effects of antihypertensive treatment in Asian populations: a meta-analysis of prospective randomized controlled studies (CARdiovascular protectioN group in Asia: CARNA). J Am Soc Hypertens 2014, 8:103-116.
242. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
243. Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
244. Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V., et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008, 359:2417-2428.
245. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.
246. Wald D.S., Law M., Morris J.K., Bestwick J.P., Wald N.J. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
247. Hermida R.C., Ayala D.E., Calvo C., Lopez J.E., Mojon A., Fontao M.J., et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 2005, 46:1053-1059.
248. Hermida R.C., Calvo C., Ayala D.E., Fernandez J.R., Covelo M., Mojon A., et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005, 23:1913-1922.
249. Hermida R.C., Ayala D.E., Fernandez J.R., Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007, 50:715-722.
250. Hermida R.C., Ayala D.E. Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 2009, 54:40-46.
251. Hermida R.C., Calvo C., Ayala D.E., Lopez J.E. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005, 46:960-968.
252. Minutolo R., Gabbai F.B., Borrelli S., Scigliano R., Trucillo P., Baldanza D., et al. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis 2007, 50:908-917.
253. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
254. Weber M.A., Julius S., Kjeldsen S.E., Brunner H.R., Ekman S., Hansson L., et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
255. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886.
256. The A.O. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. Coordinators for the ACRG.
257. Vemulapalli S., Ard J., Bakris G.L., Bhatt D.L., Brown A.S., Cushman W.C., et al. Proceedings from Duke resistant hypertension think tank. Am Heart J 2014, 167:775-788 e1.
258. Weber M.A., Jamerson K., Bakris G.L., Weir M.R., Zappe D., Zhang Y., et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013, 381:537-545.
259. Barzilay J.I., Davis B.R., Cutler J.A., Pressel S.L., Whelton P.K., Basile J., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
260. Musini V.M., Nazer M., Bassett K., Wright J.M. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014, 5:CD003824.
261. Clayton J.A., Rodgers S., Blakey J., Avery A., Hall I.P. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2006, 61:87-95.
262. Franse L.V., Pahor M., Di Bari M., Somes G.W., Cushman W.C., Applegate W.B. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000, 35:1025-1030.
263. Schnaper H.W., Freis E.D., Friedman R.G., Garland W.T., Hall W.D., Hollifield J., et al. Potassium restoration in hypertensive patients made hypokalemic byhydrochlorothiazide. Arch Intern Med 1989, 149:2677-2681.
264. Rodenburg E.M., Visser L.E., Hoorn E.J., Ruiter R., Lous J.J., Hofman A., et al. Thiazides and the risk of hypokalemia in the general population. J Hypertens 2014, 32:2092-2097.
265. Leung A.A., Wright A., Pazo V., Karson A., Bates D.W. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med 2011, 124:1064-1072.
266. Rodenburg E.M., Hoorn E.J., Ruiter R., Lous J.J., Hofman A., Uitterlinden A.G., et al. Thiazide-associated hyponatremia: a population-based study. Am J Kidney Dis 2013, 62:67-72.
267. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207.
268. Whelton P.K., Barzilay J., Cushman W.C., Davis B.R., Iiamathi E., Kostis J.B., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401-1409.
269. Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004, 43:963-969.
270. Almgren T., Wilhelmsen L., Samuelsson O., Himmelmann A., Rosengren A., Andersson O.K. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007, 25:1311-1317.
271. Tu K., Anderson L.N., Butt D.A., Quan H., Hemmelgarn B.R., Campbell N.R., et al. Antihypertensive drug prescribing and persistence among new elderly users: implications for persistence improvement interventions. Can J Cardiol 2014, 30:647-652.
272. Ernst M.E., Carter B.L., Goerdt C.J., Steffensmeier J.J.G., Phillips B.B., Zimmerman M.B., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352-358.
273. Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011, 57:689-694.
274. Patel A., Macmahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-840.
275. Roush G.C., Holford T.R., Guddati A.K. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012, 59:1110-1117.
276. Maron B.A., Leopold J.A. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010, 121:934-939.
277. Vasan R.S., Evans J.C., Larson M.G., Wilson P.W.F., Meigs J.B., Rifai N., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33-41.
278. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
279. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., Cofield S.S., Harding S.M., Calhoun D.A. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453-459.
280. Byrd J.B., Brook R.D. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens 2014, 28:3-9.
281. Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
282. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
283. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
284. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
285. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
286. Edelmann F., Wachter R., Schmidt A.G., Kraigher-Krainer E., Colantonio C., Kamke W., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013, 309:781-791.
287. Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014, 370:1383-1392.
288. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014, 311:2216-2224.
289. Matsui Y., Eguchi K., O'Rourke M.F., Ishikawa J., Shimada K., Kario K. Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study. Atherosclerosis 2011, 215:184-188.
290. Lijnen P., Staessen J., Fagard R., Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982, 49:1561-1563.
291. Chapman N., Dobson J., Wilson S., Dahlof B., Sever P.S., Wedel H., et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension 2007, 49:839-845.
292. Zannad F. Aldosterone antagonist therapy in resistant hypertension. JHypertens 2007, 25:747-750.
293. Lane D.A., Shah S., Beevers D.G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891-894.
294. de Souza F., Muxfeldt E., Fiszman R., Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010, 55:147-152.
295. Vaclavik J., Sedlak R., Plachy M., Navratil K., Plasek J., Jarkovsky J., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57:1069-1075.
296. Bobrie G., Frank M., Azizi M., Peyrard S., Boutouyrie P., Chatellier G., et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 2012, 30:1656-1664.
297. Azizi M., Perdrix L., Bobrie G., Frank M., Chatellier G., Menard J., et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens 2014, 32:2038-2044.
298. Oxlund C.S., Henriksen J.E., Tarnow L., Schousboe K., Gram J., Jacobsen I.A. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013, 31:2094-2102.
299. Karns A.D., Bral J.M., Hartman D., Peppard T., Schumacher C. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2013, 15:186-192.
300. Sica D.A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. JClin Hypertens (Greenwich) 2011, 13:639-643.
301. Kuyper L.M., Khan N.A. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014, 30(Suppl 5):S47-53.
302. Rutten F.H., Zuithoff N.P., Hak E., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010, 170:880-887.
303. Stefan M.S., Rothberg M.B., Priya A., Pekow P.S., Au D.H., Lindenauer P.K. Association between beta-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012, 67:977-984.
304. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007, 50:768-777.
305. Mentz R.J., Wojdyla D., Fiuzat M., Chiswell K., Fonarow G.C., O'Connor C.M. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013, 111:582-587.
306. Bangalore S., Parkar S., Grossman E., Messerli F.H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100:1254-1262.
307. Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010, 55:1314-1322.
308. Kirch W., Gorg K.G. Clinical pharmacokinetics of atenolol-a review. Eur J Drug Metab Pharmacokinet 1982, 7:81-91.
309. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008, 52:1482-1489.
310. Park S., Rhee M.Y., Lee S.Y., Park S.W., Jeon D., Kim B.W., et al. A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients. J Hypertens 2013, 31:813-819.
311. Zhou W.J., Wang R.Y., Li Y., Chen D.R., Chen E.Z., Zhu D.L., et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One 2013, 8:e72102.
312. Kampus P., Serg M., Kals J., Zagura M., Muda P., Karu K., et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011, 57:1122-1128.
313. Studinger P., Tabak A.G., Chen C.H., Salvi P., Othmane T.E., Torzsa P., et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens (Greenwich) 2013, 15:910-917.
314. Poirier L., Tobe S.W. Contemporary use of beta-blockers: clinical relevance of subclassification. Can J Cardiol 2014, 30(Suppl 5):S9-S15.
315. Celik T., Iyisoy A., Kursaklioglu H., Kardesoglu E., Kilic S., Turhan H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006, 24:591-596.
316. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
317. Flather M.D., Shibata M.C., Coats A.J.S., Van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
318. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
319. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
320. Brown M.J., Palmer C.R., Castaigne A., de Leeuw P.W., Mancia G., Rosenthal T., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000, 356:366-372.
321. Wang J.G., Kario K., Lau T., Wei Y.Q., Park C.G., Kim C.H., et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association. Hypertens Res 2011, 34:423-430.
322. Makani H., Bangalore S., Romero J., Wever-Pinzon O., Messerli F.H. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011, 124:128-135.
323. Black H.R., Elliott W.J., Grandits G., Grambsch P., Lucente T., White W.B., et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
324. Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Syvertsen J.O., et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
325. Slataper R., Vicknair N., Sadler R., Bakris G.L. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993, 153:973-980.
326. Elliott W.J., Ram C.V. Calcium channel blockers. J Clin Hypertens (Greenwich) 2011, 13:687-689.
327. The O.I. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
328. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992, 327:685-691.
329. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
330. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
331. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
332. Kober L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
333. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
334. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.
335. Wu H.Y., Huang J.W., Lin H.J., Liao W.C., Peng Y.S., Hung K.Y., et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013, 347:f6008.
336. Hou F.F., Zhang X., Zhang G.H., Xie D., Chen P.Y., Zhang W.R., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
337. Hsu T.W., Liu J.S., Hung S.C., Kuo K.L., Chang Y.K., Chen Y.C., et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med 2014, 174:347-354.
338. Dicpinigaitis P.V. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(Suppl 1):169S-173S.
339. Woo K.S., Norris R.M., Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995, 75:967-968.
340. Woo K.S., Nicholls M.G. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995, 40:141-144.
341. Tumanan-Mendoza B.A., Dans A.L., Villacin L.L., Mendoza V.L., Rellama-Black S., Bartolome M., et al. Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is. J Clin Epidemiol 2007, 60:547-553.
342. Brugts J.J., Arima H., Remme W., Bertrand M., Ferrari R., Fox K., et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol 2014, 176:718-723.
343. Bezalel S., Mahlab-Guri K., Asher I., Werner B., Sthoeger Z.M. Angiotensin converting enzyme inhibitor induced angioedema. Am J Med July 21 2014, [Epub ahead of print].
344. Makani H., Messerli F.H., Romero J., Wever-Pinzon O., Korniyenko A., Berrios R.S., et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012, 110:383-391.
345. Yu L.T., Zhu J., Tan H.Q., Wang G.G., Teo K.K., Liu L.S. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data. Chin Med J (Engl) 2011, 124:1763-1768.
346. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675. the Valsartan Heart Failure Trial I.
347. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
348. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
349. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012-1018.
350. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446. the ASI.
351. Solomon S.D., Appelbaum E., Manning W.J., Verma A., Berglund T., Lukashevich V., et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009, 119:530-537.
352. Seed A., Gardner R., McMurray J., Hillier C., Murdoch D., MacFadyen R., et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007, 9:1120-1127.
353. Parving H.H., Brenner B.M., McMurray J.J., de Zeeuw D., Haffner S.M., Solomon S.D., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
354. Gheorghiade M., Bohm M., Greene S.J., Fonarow G.C., Lewis E.F., Zannad F., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309:1125-1135.
355. Teo K.K., Pfeffer M., Mancia G., O'Donnell M., Dagenais G., Diaz R., et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J 2014, 35:1743-1751.
356. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283:1967-1975.
357. Kandler M.R., Mah G.T., Tejani A.M., Stabler S.N., Salzwedel D.M. Hydralazine for essential hypertension. Cochrane Database Syst Rev 2011, (11):CD004934.
358. Cohn J.N., McInnes G.T., Shepherd A.M. Direct-acting vasodilators. J Clin Hypertens (Greenwich) 2011, 13:690-692.
359. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino R., Ferdinand K., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
360. Laurent S., Schlaich M., Esler M. New drugs, procedures, and devices for hypertension. Lancet 2012, 380:591-600.
361. Ruilope L.M., Dukat A., Bohm M., Lacourciere Y., Gong J., Lefkowitz M.P. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375:1255-1266.
362. McMurray J.J.V., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med 2014, 371:993-1004.
363. Kaplan N.M., Opie L.H. Controversies in hypertension. Lancet 2006, 367:168-176.
364. Cushman W.C., Ford C.E., Cutler J.A., Margolis K.L., Davis B.R., Grimm R.H., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4:393-404.
365. Corrao G., Nicotra F., Parodi A., Zambon A., Heiman F., Merlino L., et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011, 58:566-572.
366. Corrao G., Parodi A., Zambon A., Heiman F., Filippi A., Cricelli C., et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010, 28:1584-1590.
367. Mancia G., Grassi G. Individualization of antihypertensive drug treatment. Diabetes Care 2013, 36(Suppl 2):S301-S306.
368. Weber M.A., Bakris G.L., Jamerson K., Weir M., Kjeldsen S.E., Devereux R.B., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85.
369. Bakris G.L., Sarafidis P.A., Weir M.R., Dahlof B., Pitt B., Jamerson K., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173-1181.
370. Bakris G., Briasoulis A., Dahlof B., Jamerson K., Weber M.A., Kelly R.Y., et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol 2013, 112:255-259.
371. Chalmers J., Arima H., Woodward M., Mancia G., Poulter N., Hirakawa Y., et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014, 63:259-264.
372. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
373. McAlister F.A., Zhang J., Tonelli M., Klarenbach S., Manns B.J., Hemmelgarn B.R. The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis. CMAJ 2011, 183:655-662.
374. Gupta A.K., Arshad S., Poulter N.R. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010, 55:399-407.
375. Xie L., Frech-Tamas F., Marrett E., Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin 2014, 1-27.
376. Giles T.D., Weber M.A., Basile J., Gradman A.H., Bharucha D.B., Chen W., et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 2014, 383:1889-1898.
377. Wang T.D., Chen Y.H., Huang C.H., Chen W.J., Chen M.F. Bidirectional adherence changes and associated factors in patients switched from free combinations to equivalent single-pill combinations of antihypertensive drugs. Hypertension 2014, 63:958-967.
378. Egan B.M., Bandyopadhyay D., Shaftman S.R., Wagner C.S., Zhao Y., Yu-Isenberg K.S. Initial Monotherapy and Combination Therapy and Hypertension Control the First Year. Hypertension 2012, 59:1124-1131.
379. Feldman R.D., Zou G.Y., Vandervoort M.K., Wong C.J., Nelson S.A.E., Feagan B.G. A Simplified Approach to the Treatment of Uncomplicated Hypertension: a Cluster Randomized, Controlled Trial. Hypertension 2009, 53:646-653.
380. Thom S., Poulter N., Field J., et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of cvd: the umpire randomized clinical trial. JAMA 2013, 310:918-929.
381. Jaffe M.G., Lee G.A., Young J.D., Sidney S., Go A.S. IMproved blood pressure control associated with a large-scale hypertension program. JAMA 2013, 310:699-705.
382. Tinetti M.E., Han L., Lee D.S., McAvay G.J., Peduzzi P., Gross C.P., et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med 2014, 174:588-595.
383. Beckett N., Peters R., Tuomilehto J., Swift C., Sever P., Potter J., et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012, 344:d7541.
384. Lasserson D.S., Buclin T., Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart 2011, 97:1771-1775.
385. Rosenbaum L., Shrank W.H. Taking our medicine-improving adherence in the accountability era. N Engl J Med 2013, 369:694-695.
386. Bakris G., Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction?. J Am Coll Cardiol 2014, 63:1924-1925.
387. Schlaich M.P., Sobotka P.A., Krum H., Lambert E., Esler M.D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932-934.
388. Thukkani A.K., Bhatt D.L. Renal denervation therapy for hypertension. Circulation 2013, 128:2251-2254.
389. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
390. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
391. Krum H., Schlaich M.P., Sobotka P.A., Bohm M., Mahfoud F., Rocha-Singh K., et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014, 383:622-629.
392. Messerli F.H., Bangalore S. Treatment-resistant hypertension: another Cinderella story. Eur Heart J 2013, 34:1175-1177.
393. Bhatt D.L., Kandzari D.E., O'Neill W.W., D'Agostino R., Flack J.M., Katzen B.T., et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014, 370:1393-1401.
394. Bakris G.L., Townsend R.R., Liu M., Cohen S.A., D'Agostino R., Flack J.M., et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol 2014, 64:1071-1078.
395. Messerli F.H., Bangalore S. Renal denervation for resistant hypertension?. N Engl J Med 2014, 370:1454-1457.
396. Fadl Elmula F.E., Hoffmann P., Larstorp A.C., Fossum E., Brekke M., Kjeldsen S.E., et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014, 63:991-999.
397. Lohmeier T.E., Iliescu R., Liu B., Henegar J.R., Maric-Bilkan C., Irwin E.D. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012, 59:331-338.
398. Bisognano J.D., Bakris G., Nadim M.K., Sanchez L., Kroon A.A., Schafer J., et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011, 58:765-773.
399. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008, 117:e510-e526.
400. Ma W., Zhang Y. Low rate of resistant hypertension in Chinese patients with hypertension: an analysis of the HOT-CHINA study. J Hypertens 2013, 31:2386-2390.
401. Calhoun D.A., Booth J.N., Oparil S., Irvin M.R., Shimbo D., Lackland D.T., et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014, 63:451-458.
402. Kumbhani D.J., Steg P.G., Cannon C.P., Eagle K.A., Smith S.C., Crowley K., et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013, 34:1204-1214.
403. Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125:1635-1642.
404. Smith S.M., Gong Y., Handberg E., Messerli F.H., Bakris G.L., Ahmed A., et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens 2014, 32:635-643.
405. de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
406. Daugherty S.L., Powers J.D., Magid D.J., Masoudi F.A., Margolis K.L., O'Connor P.J., et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension 2012, 60:303-309.
407. Irvin M.R., Shimbo D., Mann D.M., Reynolds K., Krousel-Wood M., Limdi N.A., et al. Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) 2012, 14:694-700.
408. Strauch B., Petrak O., Zelinka T., Rosa J., Somloova Z., Indra T., et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013, 31:2455-2461.
409. Shimbo D., Levitan E.B., Booth J.N., Calhoun D.A., Judd S.E., Lackland D.T., et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens 2013, 31:370-376.
410. Dimeo F., Pagonas N., Seibert F., Arndt R., Zidek W., Westhoff T.H. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension 2012, 60:653-658.
411. Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring: A Meta-Analysis of Randomized Trials. J Am Coll Cardiol 2011, 57:590-600.
412. Peterzan M.A., Hardy R., Chaturvedi N., Hughes A.D. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012, 59:1104-1109.
413. Su T.C., Hwang L.C., You S.L., Chen C.J. Ethnic variation in hypertension prevalence of women in Taiwan. J Hum Hypertens 2009, 23:160-167.
414. Turnbull F., Woodward M., Neal B., Barzi F., Ninomiya T., Chalmers J., et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008, 29:2669-2680.
415. Chow L.P., Lin C.C., Keyvan-Larijani E., Chang K.K. Oral contraceptives and mortality from circulatory system diseases: an epidemiologic study in Taiwan. Int J Gynaecol Obstet 1983, 21:297-304.
416. Chakhtoura Z., Canonico M., Gompel A., Scarabin P.Y., Plu-Bureau G. Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab 2011, 96:1169-1174.
417. Farquhar C.M., Marjoribanks J., Lethaby A., Lamberts Q., Suckling J.A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, (3):CD004143.
418. Su I.H., Chen Y.C., Hwang W.T., Liu Z., Su T.P., Chen T.J., et al. Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women. Menopause 2012, 19:931-941.
419. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D.M., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation 2011, 123:1243-1262.
420. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013, 122:1122-1131.
421. Visintin C., Mugglestone M.A., Almerie M.Q., Nherera L.M., James D., Walkinshaw S. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010, 341:c2207.
422. Raheem I.A., Saaid R., Omar S.Z., Tan P.C. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG 2012, 119:78-85.
423. Shekhar S., Sharma C., Thakur S., Verma S. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol 2013, 122:1057-1063.
424. LeFevre M.L. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2014, 161:819-826.
425. Tang C.H., Wu C.S., Lee T.H., Hung S.T., Yang C.Y., Lee C.H., et al. Preeclampsia-eclampsia and the risk of stroke among peripartum in Taiwan. Stroke 2009, 40:1162-1168.
426. Wang I.K., Tsai I.J., Chen P.C., Liang C.C., Chou C.Y., Chang C.T., et al. Hypertensive disorders in pregnancy and subsequent diabetes mellitus: a retrospective cohort study. Am J Med 2012, 125:251-257.
427. Lin Y.S., Tang C.H., Yang C.Y., Wu L.S., Hung S.T., Hwa H.L., et al. Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan. Am J Cardiol 2011, 107:325-330.
428. Wang I.K., Muo C.H., Chang Y.C., Liang C.C., Chang C.T., Lin S.Y., et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ 2013, 185:207-213.
429. Fontes M.L., Varon J. Perioperative hypertensive crisis: newer concepts. Int Anesthesiol Clin 2012, 50:40-58.
430. Poldermans D., Bax J.J., Boersma E., De Hert S., Eeckhout E., Fowkes G., et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009, 30:2769-2812.
431. Fleisher L.A., Beckman J.A., Brown K.A., Calkins H., Chaikof E.L., Fleischmann K.E., et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol 2009, 54:e13-e118.
432. Weksler N., Klein M., Szendro G., Rozentsveig V., Schily M., Brill S., et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery?. J Clin Anesth 2003, 15:179-183.
433. Rouleau J.L., Warnica W.J., Baillot R., Block P.J., Chocron S., Johnstone D., et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008, 117:24-31.
434. Miceli A., Capoun R., Fino C., Narayan P., Bryan A.J., Angelini G.D., et al. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2009, 54:1778-1784.
435. Bandeali S.J., Kayani W.T., Lee V.V., Pan W., Elayda M.A., Nambi V., et al. Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting. Am J Cardiol 2012, 110:919-923.
436. Radaelli G., Bodanese L.C., Guaragna J.C., Borges A.P., Goldani M.A., Petracco J.B., et al. The use of inhibitors of angiotensin-converting enzyme and its relation to events in the postoperative period of CABG. Rev Bras Cir Cardiovasc 2011, 26:373-379.
437. Benedetto U., Sciarretta S., Roscitano A., Fiorani B., Refice S., Angeloni E., et al. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg 2008, 86:1160-1165.
438. Drenger B., Fontes M.L., Miao Y., Mathew J.P., Gozal Y., Aronson S., et al. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. Circulation 2012, 126:261-269.
439. Hart G.R., Anderson R.J. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 1981, 141:1125-1127.
440. Psaty B.M., Koepsell T.D., Wagner E.H., LoGerfo J.P., Inui T.S. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990, 263:1653-1657.
441. Karachalios G.N., Charalabopoulos A., Papalimneou V., Kiortsis D., Dimicco P., Kostoula O.K., et al. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005, 59:562-570.
442. Shammash J.B., Trost J.C., Gold J.M., Berlin J.A., Golden M.A., Kimmel S.E. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001, 141:148-153.
443. Hoeks S.E., Scholte Op Reimer W.J., van Urk H., Jorning P.J., Boersma E., Simoons M.L., et al. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 2007, 33:13-19.
444. Dunkelgrun M., Boersma E., Schouten O., Koopman-van Gemert A.W., van Poorten F., Bax J.J., et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009, 249:921-926.
445. Yang H., Raymer K., Butler R., Parlow J., Roberts R. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006, 152:983-990.
446. Devereaux P.J., Yang H., Yusuf S., Guyatt G., Leslie K., Villar J.C., et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008, 371:1839-1847.
447. Bangalore S., Wetterslev J., Pranesh S., Sawhney S., Gluud C., Messerli F.H. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008, 372:1962-1976.
448. Lindenauer P.K., Pekow P., Wang K., Mamidi D.K., Gutierrez B., Benjamin E.M. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005, 353:349-361.
449. London M.J., Hur K., Schwartz G.G., Henderson W.G. Association of perioperative beta-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA 2013, 309:1704-1713.
450. Bouri S., Shun-Shin M.J., Cole G.D., Mayet J., Francis D.P. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery. Heart 2014, 100:456-464.
451. Duncan D., Nkonde-Price C., Virani S.S., Washam J.B., Fleischmann K.E., et al. Perioperative Beta Blockade in Noncardiac Surgery: a Systematic Review for the 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 64:2406-2425. [Epub ahead of print].
452. Aronson S., Dyke C.M., Stierer K.A., Levy J.H., Cheung A.T., Lumb P.D., et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008, 107:1110-1121.
453. Deeks E.D., Keating G.M., Keam S.J. Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs 2009, 9:117-134.
454. Nguyen H.M., Ma K., Pham D.Q. Clevidipine for the treatment of severe hypertension in adults. Clin Ther 2010, 32:11-23.